ING Groep NV reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 436,993 shares of the biopharmaceutical company’s stock after selling 15,789 shares during the period. ING Groep NV’s holdings in Gilead Sciences were worth $30,930,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Hall Laurie J Trustee raised its stake in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. raised its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Penserra Capital Management LLC raised its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Finally, Webster Bank N. A. raised its stake in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the last quarter. Institutional investors own 74.04% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ GILD) traded up 2.31% during mid-day trading on Thursday, hitting $83.11. 20,196,965 shares of the stock were exchanged. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $84.13. The stock has a 50 day moving average of $72.97 and a 200-day moving average of $68.86. The stock has a market cap of $108.54 billion, a price-to-earnings ratio of 9.03 and a beta of 1.21. Gilead Sciences also saw some unusual options trading on Monday. Traders purchased 19,878 put options on the stock. This represents an increase of approximately 209% compared to the typical daily volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the previous year, the firm earned $3.08 earnings per share. The firm’s quarterly revenue was down 8.2% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post $8.73 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.56%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

ILLEGAL ACTIVITY WARNING: “ING Groep NV Has $30.93 Million Position in Gilead Sciences, Inc. (GILD)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/31/ing-groep-nv-has-30-93-million-position-in-gilead-sciences-inc-gild.html.

Several equities research analysts have issued reports on GILD shares. BidaskClub upgraded shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 target price for the company in a research report on Monday, June 26th. Credit Suisse Group reiterated an “outperform” rating and set a $79.00 target price on shares of Gilead Sciences in a research report on Monday, May 15th. Gabelli reiterated a “buy” rating and set a $85.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. Eleven research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $81.07.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total value of $1,138,200.00. Following the completion of the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock worth $15,223,184 in the last quarter. 1.30% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.